# Pulmatrix Inc. (PULM)

Source: https://www.quantisnow.com/company/PULM
Generated: 2026-11-11T18:07:49.012Z

- Ticker: PULM
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2014
- SEC CIK: 0001574235
- Website: pulmatrix.com

## About

Pulmatrix, Inc., a clinical stage biopharmaceutical company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug that is in Phase 2b clinical trials for the prevention and treatment of fungal infections and allergic/hypersensitivity reactions to fungus in patients with severe lung diseases comprising asthma, cystic fibrosis, and allergic bronchopulmonary aspergillosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with lung cancer and chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.

## Latest PULM news and filings

- 2026-11-09 13:00 UTC [Eos SENOLYTIX’s PTC-2105 Reduced Semaglutide-Associated Lean-Mass Loss in Aged Mice: Data to Be Presented at 19th Sarcopenia, Cachexia & Wasting Disorders International Conference](https://www.quantisnow.com/insight/eos-senolytixs-ptc-2105-reduced-semaglutide-associated-lean-mass-loss-in-aged-mice-6780310)
- 2026-11-09 12:00 UTC [SEC Form 425] [SEC Form 425 filed by Pulmatrix Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-pulmatrix-inc-6780119)
- 2026-10-30 12:00 UTC [Eos SENOLYTIX Reports Interim Data Showing Preserved Physical Function with MitoXcel Geropeptide PTC-2105 in a Second Species, Aged-Rat Study](https://www.quantisnow.com/insight/eos-senolytix-reports-interim-data-showing-preserved-physical-function-with-6764605)
- 2026-10-30 11:24 UTC [SEC Form 425] [SEC Form 425 filed by Pulmatrix Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-pulmatrix-inc-6764529)
- 2026-10-27 13:00 UTC [SEC Form 8-K] [SEC Form 8-K filed by Pulmatrix Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-pulmatrix-inc-6758789)
- 2026-10-26 20:49 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Pulmatrix Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-pulmatrix-inc-6757862)
- 2026-10-23 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Pulmatrix Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-pulmatrix-inc-6755705)
- 2026-10-22 12:00 UTC [Eos SENOLYTIX Presents Late-Life Survival and Healthspan Data for Mitochondria-Targeted Geropeptide PTC-2105 at the 17th World Congress on Targeting Mitochondria, and Launches “Team Speedy” to Let the Public Follow Its Longest-Lived Mouse](https://www.quantisnow.com/insight/eos-senolytix-presents-late-life-survival-and-healthspan-data-for-mitochondria-targeted-6754465)
- 2026-10-22 10:05 UTC [SEC Form 425] [SEC Form 425 filed by Pulmatrix Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-pulmatrix-inc-6754113)
- 2026-10-13 10:17 UTC [SEC Form 425] [SEC Form 425 filed by Pulmatrix Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-pulmatrix-inc-6743954)
- 2026-10-07 20:06 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Pulmatrix Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-pulmatrix-inc-6740312)
- 2026-10-07 20:05 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Pulmatrix Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-pulmatrix-inc-6740294)
- 2026-10-03 01:47 UTC [SEC Form S-3] [Amendment: SEC Form S-3/A filed by Pulmatrix Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-3a-filed-by-pulmatrix-inc-6735762)
- 2026-09-28 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Pulmatrix Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-pulmatrix-inc-6726945)
- 2026-09-25 20:46 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Pulmatrix Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-pulmatrix-inc-6726648)
- 2026-09-25 20:42 UTC [SEC Form DEFM14A] [SEC Form DEFM14A filed by Pulmatrix Inc.](https://www.quantisnow.com/insight/sec-form-defm14a-filed-by-pulmatrix-inc-6726643)
- 2026-09-23 20:35 UTC [SEC Form S-4] [Amendment: SEC Form S-4/A filed by Pulmatrix Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-4a-filed-by-pulmatrix-inc-6724329)
- 2026-09-22 20:05 UTC [SEC Form 425] [SEC Form 425 filed by Pulmatrix Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-pulmatrix-inc-6722931)
- 2026-09-22 12:30 UTC [Dividends] [Eos SENOLYTIX to Highlight Next-Generation Mitochondria-Targeted Therapeutics at 17th World Congress on Targeting Mitochondria](https://www.quantisnow.com/insight/eos-senolytix-to-highlight-next-generation-mitochondria-targeted-therapeutics-at-17th-world-6722531)
- 2026-09-17 20:37 UTC [SEC Form S-4] [Amendment: SEC Form S-4/A filed by Pulmatrix Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-4a-filed-by-pulmatrix-inc-6719424)
- 2026-09-04 21:29 UTC [SEC Form S-4] [Amendment: SEC Form S-4/A filed by Pulmatrix Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-4a-filed-by-pulmatrix-inc-6706868)
- 2026-08-13 12:20 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Pulmatrix Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-pulmatrix-inc-6679484)
- 2026-08-13 12:15 UTC [SEC Form 8-K] [Pulmatrix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/pulmatrix-inc-filed-sec-form-8-k-results-of-operations-and-6679473)
- 2026-08-13 12:15 UTC [Dividends] [Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger](https://www.quantisnow.com/insight/pulmatrix-announces-second-quarter-2026-financial-results-and-progress-on-6679471)
- 2026-08-07 21:05 UTC [SEC Form S-3] [Amendment: SEC Form S-3/A filed by Pulmatrix Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-3a-filed-by-pulmatrix-inc-6672067)
- 2026-08-03 20:07 UTC [SEC Form S-4] [Amendment: SEC Form S-4/A filed by Pulmatrix Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-4a-filed-by-pulmatrix-inc-6659723)
- 2026-07-09 20:06 UTC [SEC Form S-4] [SEC Form S-4 filed by Pulmatrix Inc.](https://www.quantisnow.com/insight/sec-form-s-4-filed-by-pulmatrix-inc-6633010)
- 2026-06-16 20:36 UTC [SEC Form 10-K] [Amendment: SEC Form 10-K/A filed by Pulmatrix Inc.](https://www.quantisnow.com/insight/amendment-sec-form-10-ka-filed-by-pulmatrix-inc-6605018)
- 2026-06-05 12:00 UTC [SEC Form 425] [SEC Form 425 filed by Pulmatrix Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-pulmatrix-inc-6590570)
- 2026-06-04 10:11 UTC [SEC Form S-3] [SEC Form S-3 filed by Pulmatrix Inc.](https://www.quantisnow.com/insight/sec-form-s-3-filed-by-pulmatrix-inc-6588423)
- 2026-05-15 12:20 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Pulmatrix Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-pulmatrix-inc-6555875)
- 2026-05-15 12:20 UTC [SEC Form 8-K] [Pulmatrix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/pulmatrix-inc-filed-sec-form-8-k-results-of-operations-and-6555874)
- 2026-05-15 12:20 UTC [Pulmatrix Announces First Quarter 2026 Financial Results](https://www.quantisnow.com/insight/pulmatrix-announces-first-quarter-2026-financial-results-6555871)
- 2026-04-21 12:00 UTC [SEC Form 8-K] [Pulmatrix Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/pulmatrix-inc-filed-sec-form-8-k-regulation-fd-disclosure-other-6507765)
- 2026-04-21 12:00 UTC [Public Offering] [Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger](https://www.quantisnow.com/insight/pulmatrix-announces-closing-of-preferred-stock-transaction-as-part-of-6507755)
- 2026-04-15 20:15 UTC [SEC Form D] [SEC Form D filed by Pulmatrix Inc.](https://www.quantisnow.com/insight/sec-form-d-filed-by-pulmatrix-inc-6501314)
- 2026-03-27 21:16 UTC [SEC Form 8-K] [Pulmatrix Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/pulmatrix-inc-filed-sec-form-8-k-entry-into-a-material-6475165)
- 2026-03-26 13:11 UTC [SEC Form 425] [SEC Form 425 filed by Pulmatrix Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-pulmatrix-inc-6470323)
- 2026-03-26 12:00 UTC [Conference Announcement] [Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan](https://www.quantisnow.com/insight/pulmatrix-and-eos-senolytix-announce-merger-agreement-to-advance-novel-6470018)
- 2026-03-02 13:00 UTC [SEC Form 8-K] [Pulmatrix Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/pulmatrix-inc-filed-sec-form-8-k-termination-of-a-material-6420885)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/PULM
- Earnings history: https://www.quantisnow.com/earnings/PULM
- Dividend history: https://www.quantisnow.com/dividends/PULM
- Insider transactions: https://www.quantisnow.com/insiders/PULM
- Options chain: https://www.quantisnow.com/options/PULM
- SEC 8-K filings only: https://www.quantisnow.com/company/PULM/8-k
- RSS and alerts for PULM: https://www.quantisnow.com/docs/rss-feeds.md